News

There is little debate that vision is a critical factor in sports performance.

Results from 3 and 6 months of follow-up in a U.S. clinical trial indicate that cornea collagen cross-linking is a safe treatment that decreases corneal curvature and thickness and appears to improve vision in eyes with keratoconous or ectasia after LASIK.

The term "blepharitis" encompasses a group of conditions often divided into anterior and exterior blepharitis.

An important advance for enhancing the ease and safety of pediatric cataract surgery is 1.8mm coaxial microincision cataract surgery using a particular phaco platform, according to one expert.

The public has until March 5 to submit comments related to presentations made at a Feb. 18 public hearing at which FDA officials discussed challenges related to the premarket notification, or 510(k) process, used to review and clear certain medical devices marketed in the United States.

Lux Biosciences Inc. has submitted simultaneous regulatory filings to the FDA and the European Medicines Agency seeking marketing approval for an investigational drug, oral voclosporin (LUVENIQ or LX211), for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

The Japanese Ministry of Health, Labor and Welfare has given regulatory approval for STAAR Surgical Co. to market its implantable contact lens (Visian Implantable Collamer Lens) in that country for the treatment of myopia.

Odyssey Medical has introduced a punctal plug (Micro Flow) that is designed to provide a reversible means of partial occlusion by limiting the drainage of tears into the lacrimal duct.

Ophthalmic Women Leaders has appointed Pamela Gleeson, chief financial officer of Santen Inc., as its 2010 president. She previously served as chairwoman of the organization?s finance committee.

Bausch + Lomb has unveiled a redesigned company logo and icon. Both incorporate hues of the company?s traditional blue and green colors and introduce the plus symbol instead of the ampersand.

The Brehm Tower at the W.K. Kellogg Eye Center Complex, a $132 million, 230,000-square-foot, eight-story facility, opened March 1. It is adjacent to the existing Kellogg Eye Center research tower.

March 17 is the deadline for physicians to change their Medicare participation status for 2010.

The differential diagnosis for corneal infiltrate after refractive surgery includes several infectious and non-infectious etiologies.

Compared with sham injections, monthly injections of 0.3 or 0.5 mg of ranibizumab significantly reduced macular edema and improved best-corrected visual acuity in patients with branch retinal vein occlusion.

The Wilmer Eye Institute hosted its 27th annual Current Concepts in Ophthalmology course here March 15 to 19. The event, presented in association with Ophthalmology Times, was designed to focus on clinical use and medical issues important to the constantly evolving practice of ophthalmology.

Minority shareholders of Alcon stock have filed 12 class-action lawsuits protecting Novartis' decision to pay them less than it will pay Nestle for its Alcon shares.

Lessons learned from an ongoing retinal implant program at the University of Southern California are being applied to the development of a novel refillable and programmable drug delivery device that could be used in glaucoma management.

These days, we in the medical profession are devoting considerable attention to fashion.

Jeffrey B. Kindler, chief executive officer and chairman of the board of Pfizer Inc., received the Glaucoma Research Foundation (GRF) Catalyst Award at the organization's annual benefit and celebration.

Ophthalmologists, ophthalmic organizations, and companies operating in the ophthalmology arena are contributing to efforts to help Haiti respond to and recover from the earthquake that occurred in January.

Fera Pharmaceuticals is now shipping erythromycin and bacitracin ophthalmic ointments.

Intrastromal corneal ring segments can improve visual and refractive outcomes in eyes with keratoconus by reshaping the cornea, but collagen crosslinking may have an additive effect as an enhancement and stabilizing procedure.

All current IOL options for presbyopia correction involve some compromise, according to one ophthalmologist.

A unique fusion protein is being studied to treat age-related macular degeneration, diabetic macular edema, and macular edema secondary to central retinal vein occlusion.

The time at which an IOL is implanted following ocular trauma can be controversial.

Glaucoma is common in eyes with a keratoprosthesis implanted, and this increases the challenge of disease management, particularly IOP measurement, according to one expert.

The Wilmer Eye Institute at Johns Hopkins University School of Medicine, Baltimore, may be based near the nation's capital but, since its earliest days, the institute has considered its primary mission to improve eye care throughout the world.

Changes in the profession are on the horizon. There is a need to increase ophthalmic capacity to deal with the aging American population, among other needs specific to the profession.

The adoption of electronic medical records in the United States has been slow, but interest seems to be picking up despite a number of obstacles.

Use of IOLs during first year of life remains controversial. Currently, implanting IOLs in infants is an off-label use of these lenses.